A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels

Completed · Phase 3

Conditions studied: Phenylketonurias

In brief

The primary objective of this trial is to evaluate the safety and tolerability of long-term Phenoptin treatment in subjects with PKU.

Key facts

Study ID

NCT00225615

Run by

BioMarin Pharmaceutical

People needed

100

Starts

2005-11-01

Expected to finish

2006-06-01

Last updated by the study team

2009-08-20

Who can join

Age: 8 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 8 years of age and older
• Prior successful participation in Study PKU-003
• Willing and able to provide written informed consent or assent and written informed consent (if required) by a parent or legal guardian
• For females of child-bearing potential only: Negative urine pregnancy test within 24 hours prior to enrollment. Women using acceptable birth control measures must agree to continue to use those measures while participating in the study
• Willing and able to comply with study procedures
• Willing to continue current diet unchanged while participating in the study

You may not qualify if…

• Perceived to be unreliable or unavailable for study participation or, if under the age of 18, have parents or legal guardians who are perceived to be unreliable or unavailable
• Withdrew from, or otherwise did not successfully complete, study PKU-003, except for subjects who were removed from the study because their blood Phe exceeded the alert level
• Expected to require any investigational agent or vaccine prior to completion of all scheduled study assessments
• Pregnant or breastfeeding, or planning pregnancy
• Concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin-dependent diabetes)
• Requirement for concomitant treatment with any drug known to inhibit folate synthesis (e.g., methotrexate)
• Concurrent use of levodopa

Where it is running

• Study site — Los Angeles, California, United States
• Study site — Oakland, California, United States
• Study site — Sacramento, California, United States
• Study site — San Jose, California, United States
• Study site — New Haven, Connecticut, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — St Louis, Missouri, United States
• Study site — New York, New York, United States
• Study site — Portland, Oregon, United States
• Study site — Dallas, Texas, United States
• Study site — Salt Lake City, Utah, United States
• Study site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.